Enveda Biosciences gets FDA go-ahead for Phase 1 trial of oral drug ENV-6946 for IBD.

Enveda Biosciences has received FDA approval to begin a Phase 1 clinical trial for ENV-6946, an oral small molecule drug for inflammatory bowel disease (IBD), marking its third candidate in clinical development. The drug, derived from natural chemistry, aims to address unmet needs in IBD treatment, including poor adherence, variable responses, and limited effective oral options. The trial will evaluate the drug’s safety and potential efficacy in patients with IBD. The milestone coincides with the upcoming 4th Precision Medicine in IBD Summit in Boston, where Enveda’s IBD franchise head will discuss challenges in treating Crohn’s disease and ulcerative colitis.